Virtual Biopsy by Using Artificial Intelligence-based Multimodal Modeling of Binational Mammography Data
Vesna Barros1, Tal Tlusty1, Ella Barkan1
1From the AI for Accelerated Healthcare & Life Sciences Discovery, IBM R&D Laboratories, University of Haifa Campus, Mount Carmel, Haifa 3498825, Israel (V.B., T.T., E.B., E.H., M.R.Z.); The Hebrew University of Jerusalem, Ein Kerem Campus, Jerusalem, Israel (V.B., M.R.Z.); IBM Watson Health, Cambridge, Mass (D.G.); RadPartners, Jefferson Radiology, East Hartford, Conn (D.G.); Department of Imaging, Assuta Medical Center, Tel Aviv, Israel (M.G.); and Ben-Gurion University Medical School, Be'er Sheva, Israel (M.G.).
Abstract:
Background Computational models based on artificial intelligence (AI) are increasingly used to diagnose malignant breast lesions. However, assessment from radiologic images of the specific pathologic lesion subtypes, as detailed in the results of biopsy procedures, remains a challenge. Purpose To develop an AI-based model to identify breast lesion subtypes with mammograms and linked electronic health records labeled with histopathologic information. Materials and Methods In this retrospective study, 26 569 images were collected in 9234 women who underwent digital mammography to pretrain the algorithms. The training data included individuals who had at least 1 year of clinical and imaging history followed by biopsy-based histopathologic diagnosis from March 2013 to November 2018. A model that combined convolutional neural networks with supervised learning algorithms was independently trained to make breast lesion predictions with data from 2120 women in Israel and 1642 women in the United States. Results were reported using the area under the receiver operating characteristic curve (AUC) with the 95% DeLong approach to estimate CIs. Significance was tested with bootstrapping. Results The Israeli model was validated in 456 women and tested in 441 women (mean age, 51 years ± 11 [SD]). The U.S. model was validated in 350 women and tested in 344 women (mean age, 60 years ± 12). For predicting malignancy in the test sets (consisting of 220 Israeli patient examinations and 126 U.S. patient examinations with ductal carcinoma in situ or invasive cancer), the algorithms obtained an AUC of 0.88 (95% CI: 0.85, 0.91) and 0.80 (95% CI: 0.74, 0.85) for Israeli and U.S. patients, respectively (P = .006). These results may not hold for other cohorts of patients, and generalizability across populations should be further investigated. Conclusion The results offer supporting evidence that artificial intelligence applied to clinical and mammographic images can identify breast lesion subtypes when the data are sufficiently large, which may help assess diagnostic workflow and reduce biopsy sampling errors. Published under a CC BY 4.0 license. Online supplemental material is available for this article.
More Related Videos
05:49Author Spotlight: Advancing CBCT and Digital Dental Image Integration with AI-Assisted Digitization
Published on: February 23, 2024
07:53Author Spotlight: Advancing 3D Modeling for Enhanced Diagnosis and Treatment of Pulmonary Nodules in Early-Stage Lung Cancer
Published on: October 13, 2023
